Overview of pneumococcal serotypes and genotypes causing diseases in patients with chronic obstructive pulmonary disease in a Spanish hospital between 2013 and 2016 by Shoji, Hisashi et al.
© 2018 Shoji et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Infection and Drug Resistance 2018:11 1387–1400
Infection and Drug Resistance Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1387
O R I G I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IDR.S165093
Overview of pneumococcal serotypes and 
genotypes causing diseases in patients with 
chronic obstructive pulmonary disease in a 












1Microbiology Department, Hospital 
Universitari de Bellvitge, IDIBELL, 
University of Barcelona, Barcelona, 
Spain; 2CIBER de Enfermedades 
Respiratorias, ISCIII, Madrid, Spain; 
3Respiratory Medicine Department, 
Hospital Universitari de Bellvitge, 
IDIBELL, University of Barcelona, 
Barcelona, Spain; 4Pneumococcal 
Reference Laboratory, Centro 
Nacional de Microbiología, ISCIII, 
Madrid, Spain
*These authors contributed equally to 
this work
Background: Streptococcus pneumoniae is an important pathogen in chronic obstructive 
pulmonary disease (COPD). We aimed at showing the recent changes in the epidemiology of 
pneumococcal diseases in patients with COPD, especially after the introduction of the 13-valent 
pneumococcal conjugate vaccine (PCV13).
Methods: From 2013 to 2016, strains causing invasive pneumococcal disease (IPD), non-
bacteremic pneumococcal pneumonia (non-BPP), and acute exacerbation of COPD (AE-COPD) 
were prospectively included. Antimicrobial susceptibility testing, serotyping, and genotyping 
were analyzed.
Results: We collected 345 pneumococci from 286 COPD patients (57 IPD, 78 non-BPP, and 
210 AE-COPD). The most frequent serotypes were serotypes 3 (14.0%), 8 (14.0%), and 12F 
(8.8%) in IPD; serotypes 3 (16.7%), 11A (9%), 9L/N (7.7%), and 23A (7.7%) in non-BPP; 
and serotypes 11A (11%), nontypeable (11%), and 6C (10%) in AE-COPD. Resistance rates 
were highest among AE-COPD strains. Penicillin resistance was associated with serotypes 11A 
(CC156) and 19A (CC320 and CC230). Compared with previous studies, fluoroquinolone resis-
tance in AE-COPD increased (9.5%), PCV13 serotypes decreased (31.6%, 26.9%, and 16.7% 
for IPD, non-BPP, and AE-COPD, respectively), and serotype 11A-CC156 in AE-COPD and 
serotype 8 in IPD increased.
Conclusion: The epidemiology of pneumococcal disease in COPD changed after the introduc-
tion of PCV13 in children. Increases in the highly invasive serotype 8 among patients with IPD 
and in serotype 11A-CC156 among patients with AE-COPD could compromise the ability of 
current PCVs to prevent diseases. Vaccines with a greater coverage could improve the benefits 
of adult vaccination.
Keywords: Streptococcus pneumoniae, pneumococcal conjugate vaccine, chronic obstructive 
pulmonary disease, invasive pneumococcal disease
Introduction
Chronic obstructive pulmonary disease (COPD) is a major public health problem in 
developed countries which is characterized by high morbidity and mortality, principally 
due to recurrent acute exacerbations (AEs).1 According to the World Health Organiza-
tion, 65 million people were estimated to suffer from COPD, among which there were 
more than three million deaths in 2005.2 However, its prevalence has since increased, 
and COPD is now the third leading cause of death worldwide.3 Patients with severe and 
very severe COPD are classified by the Global Initiative for Chronic Obstructive Lung 
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Disease (GOLD) as GOLD III and GOLD IV, respectively, 
and usually have numerous AEs per year.4
Although several factors can lead to AE of COPD (AE-
COPD), viral and bacterial respiratory tract infections are the 
most common. Among these, Streptococcus pneumoniae is 
responsible for >15% of AE-COPD.5 Therefore, the GOLD 
2017 COPD guidelines recommended the administration of 
pneumococcal vaccines (mainly the 23-valent pneumococcal 
polysaccharide vaccine [PPSV23] and the 13-pneumococcal 
conjugated vaccine in adults) to prevent infection in patients 
with COPD.5,6 In pneumococci, the capsular polysaccharide 
is the most important virulence factor, and its diversity is 
the basis of both serotyping and vaccine formulation, with 
>90 serotypes known to exist.7 The different composition of 
the pneumococcal capsular polysaccharide (serotype) has 
been related to the invasive disease potential. The invasive-
ness classification is made regarding the prevalence of the 
different serotypes among colonization or invasive disease.7
The introduction of the 7-valent pneumococcal conju-
gate vaccine (PCV7) for children in early 2000, which was 
replaced by 13-valent pneumococcal conjugate vaccine 
(PCV13) in 2010, reduced the incidence of invasive pneu-
mococcal disease (IPD) in all age-groups and changed the 
epidemiology of pneumococcal infections.8–10 Since 2017, 
PCV13 has been included in the official vaccination calendar 
for children aged >5 years. For adults with high-risk condi-
tions, the proposed schedule is PCV13 followed by a booster 
with PPSV23 2 months later, while PPSV23 is recommended 
for adults in general.11
In pneumococci, antibiotic resistance has been associated 
with diseases such as COPD that receive multiple courses 
of antibiotics for exacerbations.12,13 In previous studies, we 
described changes in antimicrobial susceptibility and in 
the serotype and genotype distributions of pneumococci 
responsible for AE-COPD over a 12-year period, including 
the early PCV13 period.14
In this study, we show the recent changes in antimicrobial 
susceptibility and in pneumococcal serotypes and geno-
types responsible for AE-COPD in the late PCV13 period 
(2013–2016). In addition, we analyze the invasiveness of 
pneumococcal serotypes among COPD patients.
Materials and methods
Ethics
Written informed consent was not considered necessary 
for the study, because it was a retrospective analysis of our 
usual daily work. However, patient data were anonymized 
for analysis, and any confidential information was protected 
according to the required national standards. This research 
was approved by the Clinical Research Ethics Committee 
of Bellvitge University Hospital (PR378/17), which also 
approved the publication of the research.
Hospital setting, study design, and 
bacterial strains
This prospective laboratory-based study included all pneumo-
coccal isolates collected from adult patients (>18 years) with 
IPD and non-IPD who attended the Hospital Universitari de 
Bellvitge. For the present study, isolates were selected if col-
lected from patients with COPD in the period of 2013–2016.15
The COPD status of the patients was established accord-
ing to the GOLD criteria.16 IPD was defined as the isolation 
of S. pneumoniae from a normally sterile site plus clinical 
symptoms of infection. Non-bacteremic pneumococcal 
pneumonia (non-BPP) was defined as the isolation of S. 
pneumoniae from a good-quality sputum sample (<10 
squamous cells and >25 leucocytes per low-power field) in 
a patient with clinical signs and symptoms of pneumonia 
(fever, X-ray changes, and chest pain). Finally, an AE-
COPD was defined as any sustained increase in respira-
tory symptoms from baseline that required an increase in 
regular medication and hospital treatment. Two AE-COPD 
episodes were considered different when they occurred at 
least 1-month apart. Persistent strains were defined when two 
isolates of the same patient collected in different episodes 
had identical serotype and genotype.
Pneumococcal strains were identified by matrix-assisted 
laser desorption/ionization–time of flight plus optochin sus-
ceptibility and/or bile solubility. Antimicrobial susceptibility 
was tested by microdilution according to the criteria of the 
Clinical Laboratory Standard Institute.17,18
To understand the impact of PCV13 introduction in chil-
dren on the serotype and genotype distribution of AE-COPD 
isolates, the study results for 2013–2016 were compared with 
data previously published by our group.14 PCVs were licensed 
for childhood vaccination in 2001 (PCV7), 2009 (10-valent 
pneumococcal conjugate vaccine), and 2010 (PCV13). 
However, vaccination has been voluntary until 2017 because 
PCVs were not subsidized by official programs; therefore, 
the childhood vaccination rate in the study period was esti-
mated to be about 60%.19 Currently, PCV13 is subsidized by 
the official program for children (2, 4, and 11 months).11,19
Serotyping and molecular typing
Serotyping of AE-COPD strains was carried out by multi-
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COPD pneumococcal serotypes and genotypes
described methodology (https://www.cdc.gov/streplab/pcr.
html). The invasive isolates and those in which the serotype 
was not identified by PCR were typed by Quellung reaction 
at the Spanish Reference Laboratory for Pneumococci in 
Majadahonda, Madrid, Spain. Genotyping was performed 
by pulse field gel electrophoresis (PFGE) and/or multilocus 
sequence typing (MLST) as described previously.15 All pneu-
mococcal strains were tested by PFGE, and representative 
strains of the major PFGE clusters (defined by those account-
ing for four or more isolates) were tested by MLST. When a 
major PFGE cluster accounted for isolates of more than one 
serotype, at least one isolate of each serotype–PFGE cluster 
combination was subjected to MLST.
Statistical analysis
Statistical analyses were performed using SPSS for Windows, 
Version 14.0 (SPSS Inc., Chicago, IL, USA). Serotypes, 
genotypes, and antimicrobial susceptibility in patients with 
pneumonia and AE-COPD were compared using the χ2 or 
Fisher’s exact tests, as appropriate. Two-sided p-values <0.05 
were considered statistically significant.
Results and discussion
Patient characteristics and antibiotic 
susceptibility
During the study period, 1409 pneumococcal strains were 
isolated in our hospital. Of these, 1064 were excluded because 
they were collected from non-COPD patients (n=949), were 
isolated from asymptomatic COPD patients (n=107), or were 
not available for serotype analysis (n=8). Figure 1 shows the 
workflow of the study. Consequently, we finally included 345 
pneumococcal isolates from 286 adult patients with COPD.
The median age of the 286 included patients was 72 years 
(range 38–94), and most (85.5%) of the patients were male. 
Of the 345 isolates, we collected 57 (16.5%) during episodes 
of IPD, 78 (22.6%) during episodes of non-BPP, and 210 
(60.9%) during AE-COPD (Figure 1). Among the IPD epi-
sodes, 45 were bacteremic pneumonia, three were meningitis, 
seven were primary bacteremia, and two were others. The 
severity of airflow obstruction at the time of infection was 
known in 284 cases, and 24 cases were classified as GOLD 
I (7%), 90 as GOLD II (26.1%), 111 as GOLD III (32.2%), 
and 59 as GOLD IV (17.1%) as shown in Table 1. The GOLD 
status was not known in the remaining 61 cases because they 
were classified as having COPD based on clinical diagnosis, 
without a spirometric evaluation.
In 33 patients, more than one isolate was collected 
from different episodes occurring >1 month apart (ranging 
from two to nine episodes per patient). Among them, 19 
patients had more than two AE-COPD episodes, one patient 
had two non-BPP episodes, and two patients had two IPD 
episodes; 10 patients had ≥1 AE-COPD and ≥1 non-BPP 
episodes; finally, 1 patient had 1 AE-COPD episode and 1 
IPD episode. Comparing serotypes and genotypes between 
episodes, persistent strains (defined as both isolates sharing 
identical serotypes and genotypes) were only identified for 
AE-COPD in 10 patients. However, the serotype–genotype 
combinations for each of these persistent strains were 
different (6C-ST386, 11A-ST62, 11A-ST6521, 19A-ST81, 
19A-ST320, 19A-ST276, 16F-ST30, 19F-ST8359, and 23B-
ST2372). Although we have found a high diversity among 
these strains when compared with previous results, the rate 
of persistence among patients with more than one episode 
remained stable.20
Table 2 summarizes the antibiotic nonsusceptibility 
of pneumococcal isolates collected during IPD, non-
BPP, and AE-COPD episodes. Although most isolates 
were collected from respiratory infections, the β-lactam 
meningeal break points were also used in the analysis 
due to its epidemiological value. Overall, there were 
differences in susceptibility between groups, including 
β-lactams, macrolides, and fluoroquinolones, with higher 
resistance rates among AE-COPD isolates than among 
isolates from other infection types. This fact could reflect 
the high usage of antibiotics to treat AE-COPD, and 
it could favor the selection of drug-resistant strains.21 
Compared with previous reports, antibiotic resistance 
rates for pneumococcal disease in patients with COPD 
remained stable in the study period, with the exception 
of levofloxacin, which increased from 3.5% in the period 
of 2001–2008 to 9.52% in the period of 2013–2016 
among AE-COPD isolates. It is possible that the use of 
fluoroquinolones in these patients has favored the selection 
of mutations in the quinolone resistance–determining 
regions among persistent strains.15,21
Current distribution of pneumococcal 
serotypes
Figure 2 shows the distribution of pneumococcal serotypes 
by disease type. Overall, as shown in Table 3, serotypes 11A 
(n=33, 9.6%), nontypeable (n=27, 7.8%), 3 (n=26, 7.5%), 
6C (n=25, 7.2%), and 19A (n=21, 6.1%) were the most 
frequent. However, differences were observed according to 
the disease type: Serotypes 3 (n=8, 14.0%), 8 (n=8, 14.0%), 
and 12F (n=5, 8.8%) were the most frequent in IPD; serotypes 
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23A (n=6, 7.7%) were the most frequent in non-BPP; and 
serotypes 11A (n=23, 11%), non-typeable (n=23, 11%), 
and 6C (n=21, 10%) were the most frequent in AE-COPD. 
The respective coverages of vaccines for IPD, non-BPP, and 
AE-COPD were as follows: 5.3%, 1.3%, and 7.6% for PCV7; 
31.6%, 26.9%, and 16.7% for PCV13; and 35.1%, 30.8%, 
and 20.0% for the upcoming PCV15.22
Compared with previous reports, the frequency of 
PCV13 serotypes in AE-COPD isolates has decreased 
between periods, from 55.1% in 2001–2004, to 40.3% 
in 2005–2008, to 28.8% in 2009–2012, and to 16.7% in 
2013–2016 as shown in Figure 3.14,15 These likely reflect a 
serotype replacement on pneumococcal disease in COPD 
patients probably by the impact of childhood vaccination. 
In fact, a prospective multicenter study performed in Spain 
after the introduction of PCV13 for children showed a 50% 
reduction of adult IPD due to PCV13.19 Despite this indirect 
and beneficial impact of childhood vaccination, PCV13 
serotypes are still found in COPD patients. This fact could 
be justified by several factors: first, COPD patients could 
be persistently colonized by pneumococci (even PCV13 
serotypes); second, COPD patients are not vaccinated with 
PCV13; and third, there are PCV13 serotypes rarely found 
in children (ie, serotype 3); then, an exclusively childhood 
vaccination strategy with PCV13 could barely impact on the 
prevalence of these serotypes in adults. Then, the prevention 
of pneumococcal infections in COPD patients deserves 
other strategies. In fact, a recent prospective observational 
study of patients with COPD demonstrated that those who 
did not receive the PCV13 vaccine had triple the risk of 




























Figure 1 Flowchart representing the methodology used for the selection of Streptococcus pneumoniae isolates in patients with COPD.
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COPD pneumococcal serotypes and genotypes
COPD-related hospitalizations compared with vaccinated 
patients.23 The use of PCVs to prevent pneumococcal 
disease in adult patients with COPD could improve the 
beneficial effects of childhood vaccination, especially 
for the prevention of IPD and non-BPP. In contrast, 
the high frequency of nonvaccine serotypes among the 
AE-COPD isolates emphasizes the need for broader vaccine 
strategies. The sequential vaccination with PCV13 plus the 
PPSV23 could improve the benefits in at-risk patients, as 
recommended.6 Many penicillin-resistant strains (minimum 
inhibitory concentration [MIC] >1; n=48) were associated 
with serotypes 11A (all related to CC156; n=21), 19A 
(mainly related to CC320 or CC230; n=11), and 19F (mainly 
related to ST8359; n=5). Macrolide resistance was mainly 
associated with serotypes 6C (CC386) and 19A (CC320 
and CC230). Moreover, these latter two serotypes, and their 
related clonal complexes, were also the major contributors 
to multidrug resistance.
Invasiveness of serotypes
Three serotypes (8, 3, and 12F) were more prone to cause 
invasive disease based on their significant ORs comparing 
Table 1 Characteristics of COPD patients with pneumococcal infections
IPD non-BPP AE-COPD
% Number of isolates % Number of isolates % Number of isolates
Total 57 16.5 78 22.60 210 60.9
Sex (male) 37 64.9 68 87.18 190 90.5
Age (median) 69 73 73
COPD GOLD status
GOLD I 8 14.0 7 9 9 4.3
GOLD II 16 28.1 27 34.6 47 22.4
GOLD III 13 22.8 29 37.2 69 32.9
GOLD IV 2 3.5 8 10.2 49 23.3
Not available 18 31.6 7 9 36 17.1
Abbreviations: AE-COPD, acute exacerbation of COPD; COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; 
IPD, invasive pneumococcal disease; non-BPP, non-bacteremic pneumococcal pneumonia.
Table 2 Antibiotic nonsusceptibility rates of pneumococcal isolates collected from IPD, non-BPP, and AE-COPD in the period of 
2013–2016
Antibiotics
IPD non-BPPa AE-COPD Total
n=57 %R n=78 %R n=210 %R n=345 %R
Penicillinb 15 26.32 15 19.23 96 45.71c 126 36.52
0.12–1 mg/L 10 17.54 8 10.26 60 28.57 78 22.61
2 mg/L 3 5.26 3 3.85 26 12.38 32 9.28
≥4 mg/Ld 2 3.51 4 5.13 10 4.76 16 4.64
Cefotaximeb 6 10.53 8 10.26 25 11.90 39 11.30
1 mg/L 5 8.77 5 6.41 20 9.52 30 8.70
≥2 mg/Ld 1 1.75 3 3.85 5 2.38 9 2.61
Amoxicillind 2 3.51 5 6.41 25 11.90c 32 9.28
4 mg/Ld 1 1.75 5 6.41 21 10.00 27 7.83
≥8 mg/Ld 1 1.75 0 0.00 4 1.90 5 1.45
Erythromycin 9 15.79 11 14.10 80 38.10c 100 28.99
Clindamycin 8 14.04 9 11.54 72 34.29c 89 25.80
Tetracycline 18 31.58 16 20.51 87 41.43c 121 35.07
Chloramphenicol 6 10.53 5 6.41 9 4.29 20 5.80
Cotrimoxazole 12 21.05 16 20.51 69 32.86 97 28.12
Levofloxacin 1 1.75 1 1.28 20 9.52 22 6.38
Multiresistance 12 21.05 10 12.82 77 36.67c 99 28.70
Notes: aThere were no statistically significant differences among resistance rates of IPD and non-BPP; boverall nonsusceptible following meningeal criteria; cresistance rates 
of AE-COPD pneumococci significantly higher (p<0.05) than among IPD or non-BPP isolates; dnonsusceptible for nonmeningeal infections. %R indicates the percentage of 
resistance to each antibiotic among the number that is given on each group (IPD, non-BPP, AECOPD and Total).




































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





IPD with AE-COPD isolates (Table 3). In a recent study 
performed in Sweden, serotype 8 has been shown to have 
high invasive disease potential based on the difference in 
serotype distribution between nasopharyngeal colonization 
(a prerequisite to disease) and invasive disease.24 Moreover, 
we observed a notable increase of serotype 8 among IPD 
(from 6.4% in the period of 2001–2008 to 14% in the period 
of 2013–2016), as has been reported in other European 
countries.25,26 The invasive disease potential of serotype 3, by 
contrast, is more controversial. For example, a low disease 
potential or lineage-dependent invasive disease potential has 
been shown for this serotype,7,27 even though the study from 
Sweden showed this serotype to have high invasiveness.24 In 
the same way, our finding of the low invasiveness of serotype 
11A is in agreement with the findings of the Swedish report 
on this serotype.24
Regarding invasive disease potential, slight differences 
in methodology should be considered when drawing 
conclusions. In our series, the frequency of serotype 3 isolates 
was compared between two types of pneumococcal disease 
(AE-COPD and IPD). However, classical studies regarding 
the invasiveness of pneumococcal serotypes compared the 
proportions of serotypes causing IPD or colonizing children 
(no disease). Despite these differences, serotype 3 appears 
Table 3 Serotype distribution among IPD and AE-COPD in COPD patients
IPD AE-COPD OR 95% CI
Number of isolates % Number of isolates %
Total 57 16.5 210 60.9
Serotype
PCV7 3 5.26 16 7.6 0.67 (0.19–2.39)
4 0 0 0 0 – (–/–)
6B 0 0 1 0.5 0.00 (0/–)
9V 0 0 1 0.5 0.00 (0/–)
14 2 3.51 0 0 ∞ (–/∞)
18C 0 0 2 1 0.00 (0/–)
19F 1 1.75 11 5.2 0.32 (0.04–2.55)
23F 0 0 1 0.5 0.00 (0/–)
PCV13 18 31.6 35 17 2.31 (1.18–4.49)
Additional PCV13 15 26.3 19 9 6.50 (3.03–13.91)
1 1 1.75 0 0 0.00 (0/–)
3 8 14.0a 5 2.4 6.69 (2.10–21.35
5 0 0 0 0 – (–/–)
6A 0 0 0 0 – (–/–)
7F 3 5.26 1 0.5 11.61 (1.18–113.84)
19A 3 5.26 13 6.2 0.84 (0.23–3.06)
Non-PCV13 39 68.4 175 83 0.43 (0.22–0.84)
6C 3 5.26 21 10 0.50 (0.14–1.74)
8 8 14.0a 2 1 16.98 (3.5–82.47)
9N/L 3 5.26 5 2.4 2.28 (0.53–9.83)
10A 2 3.51 8 3.8 0.92 (0.19–4.45)
11A 3 5.26 23 11 0.45 (0.13–1.56)
12F 5 8.8a 0 0 ∞ (–/∞)
16F 0 0 7 3.3 0.00 (0/–)
17F 2 3.51 2 1 3.80 (0.52–27.45)
22F 2 3.51 6 2.9 1.23 (0.24–6.29)
23A 3 5.26 10 4.8 1.11 (0.29–4.17)
23B 3 5.26 8 3.8 1.40 (0.36–5.46)
24F 0 0 8 3.8 0.00 (0/–)
31 3 5.26 13 6.2 0.84 (0.23–3.06)
35B 2 3.51 8 3.8 0.91 (0.18–4.44)
Others 0 0 54 26 0.00 (0/–)
Note: aSerotypes whose frequency is significantly higher among IPD than that among AE-COPD.
Abbreviations: AE-COPD, acute exacerbation of COPD; COPD, chronic obstructive pulmonary disease; IPD, invasive pneumococcal disease; PCV7, 7-valent pneumococcal 
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COPD pneumococcal serotypes and genotypes
to be a major cause of pneumococcal disease in patients 
with COPD.
Changes in serotype distribution in the 
late PCV13 period: emerging clones in 
AE-COPD
Although the impact of PCV13 introduction has been 
extensively analyzed for both children and adults with IPD, 
information about its impact of clonal composition is scarce. 
Such knowledge of the genetic background of serotypes is 
important when seeking to identify emerging or recombinant 
clones. Therefore, we compared the current serotype distri-
bution of AE-COPD isolates with a historical period (Table 
S1).14 As expected, most of the PCV13 serotypes (3, 23F, 14, 
9V, and 6A) decreased significantly (Table S1). Despite the 
decrease in the frequency of serotype 3 among AECOPD 
episodes over the study period, this serotype remains as a 
leading cause of IPD (together with serotype 8, 14% each). 
Although we did not have an explanation for this event, we 
have noticed a progressive change in the clonal distribution of 
serotype 3 in COPD and other adult patients in our area.10,19 
Currently, the major clone is the widely disseminated sero-
type 3 clone (CC180) that probably could have advantages 
to improve invasiveness. On the other hand, the frequency 
of serotype 19A remained stable (6.2%–6.6%), which was 
mainly linked to two multidrug-resistant lineages (CC230 
and ST320; shown in Figure 4; Tables S2 and S3). Among 
the non-PCV13 serotypes, there were notable increases in the 
frequencies of serotypes 6C, 11A, and 15B/C.
Perhaps the most noteworthy result in this comparison 
was the shift in the clonal composition of serotype 11A, 
with an overall decrease in CC62 that paralleled the increase 
in CC156, which is related to ST6521 (Figure 4; Table S3). 
Moreover, it was interesting to analyze the changes in the 
prevalence of CC156 among AE-COPD episodes. In a previ-
ous study, we showed that it decreased mainly in response 
to decreases in vaccine serotypes 9V and 14.14 However, in 
the period of 2013–2016, there was a significant increase in 
CC156, reaching frequencies similar to those prior to the 
introduction of PCVs, but with a change in the serotype com-
position. Whereas all CC156 isolates belonged to serotypes 
14 and 9V in the periods of 2001–2004 and 2005–2008, 
nearly all CC156 isolates (19 of 20 isolates) were serotype 
11A in the period of 2013–2016 (Figure 4; Table S3). This 
emerging recombinant clone was first detected in 2007 in 
Spain, when it was associated with both invasive and non-
invasive diseases.28
The CC156 recombinant clone has shown a high poten-
tial to be able to avoid the host immune response and a high 
ability to produce biofilms, both of which are important 
in the pathogenesis of AE-COPD.28 Moreover, our pres-
ent results have shown that the frequency of this vaccine 























3 8 12F 11A 23A 9N/L 19A 31 23B 6C 7F
Serotypes
35B 10A 22F 17F 14 19F 15B/CNT 16F 24F
Figure 2 Distribution of pneumococcal serotypes among IPD, non-BPP, and AE-COPD.
Notes: Bars represent the proportion of each serotype among different disease types. Gray bars show IPD, white bars show non-BPP isolates, and black bars show AE-
COPD isolates.
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2001–2004 2005–2008 2009–2012 2013–2016
Figure 3 Distribution of pneumococcal serotypes by vaccine groups among AE-COPD isolates.
Notes: Black bars show PCV7 serotypes, white bars show additional PCV13 serotypes, dark gray bars show additional PCV15 serotypes, and gray bars show non-PCV13 
serotypes. 
Abbreviations: AE-COPD, acute exacerbation of chronic obstructive pulmonary disease; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal 






























































Figure 4 Main changes in the distribution of genotype–serotype combinations among AE-COPD.
Notes: Bars showed the proportion of the different genotype–serotype combinations among AE-COPD pneumococci. Colors differentiate periods.
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COPD pneumococcal serotypes and genotypes
COPD. The combination of damaged bronchial epithelium 
and impaired immunity of these patients, together with the 
pathogenic characteristics of this recombinant strain, could 
account for this rise. The most worrisome feature, however, 
is the high-level resistance of this clone to amoxicillin, 
which is frequently prescribed for AE-COPD. Amoxicillin 
use could even compromise the evolution and outcomes 
of the disease.
Another important issue is the declining frequency of 
CC63. Although this showed an increasing trend in the early 
PCV13 period (2009–2012), its frequency is currently very 
low. However, clonal fluctuations could account for these 
changes.10 The continuous increase of CC386 (serotype 6C) is 
yet another important issue, because this multidrug-resistant 
clone has resistance to macrolides and lincosamides and 
has been detected in neighboring European countries such 
as France or Portugal as a cause of pneumococcal disease, 
especially in adults.29–31 It is possible that the increased 
use of azithromycin to treat patients with advanced COPD 
pathology, because of their possible anti-inflammatory activ-
ity, could have contributed to the high prevalence of this 
macrolide- and multidrug-resistant clone.32
We observed the spread of two other clones: CC1684 
related to serotype 31 and CC2372 related to serotype 23B, 
as previously described.33,34 Both were sporadically detected 
before 2013 and in this study accounted for 6.2% and 3.8% of 
AE-COPD isolates, respectively. CC1684 is a β-lactam- and 
macrolide-susceptible clone that has been identified among 
cotrimoxazole-resistant and cotrimoxazole-susceptible 
serotype 31 isolates colonizing children in Thailand.34 All 
serotype 23B-ST2372 isolates were penicillin-resistant (MIC 
range =0.25–1 µg/mL) and cotrimoxazole-resistant.
The major limitation of our study is that it was performed 
in a single hospital and only reflects the local epidemiology 
of patients with COPD in this area. However, performing a 
comparison with a historical series allowed us to analyze the 
recent changes in pneumococcal diseases in this population. 
Another limitation is the lacking data about PPSV23 vac-
cination in these patients. 
Conclusion
We have shown a change in the serotype distribution of 
disease-causing pneumococci in patients with COPD. 
The spread of a serotype 11A recombinant clone (11A-
CC156) as a cause of AE-COPD is worrisome because it 
has strong β-lactam resistance. Another worrisome change 
is the increase in the highly invasive serotype 8 that could 
 compromise the effectiveness of current conjugate vaccines 
in the prevention of IPD in COPD patients. New conjugated 
vaccines that include these emerging serotypes, or preferably 
nonserotype vaccines, are needed to preserve the benefits of 
vaccination in patients with COPD and the overall population.
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COPD pneumococcal serotypes and genotypes
Table S1 Serotype distribution among acute exacerbation episodes of COPD patient by period of time
Total 2001–20041 2005–20081 2009–20121 2013–2016
n % n % n % n % n %
Serotype 772 136 211 198 210
PCV7 130 16.84 54 39.71 37 17.54 23 11.62 16 7.62a,b,d
19F 45 5.83 15 11.03 6 2.84 13 6.57 11 5.24
18C 8 1.04 4 2.94 2 0.95 0 0.00 2 0.95
23F 26 3.37 9 6.62 11 5.21 5 2.53 1 0.48a,b,d
9V 19 2.46 11 8.09 5 2.37 2 1.01 1 0.48d
6B 7 0.91 5 3.68 1 0.47 0 0.00 1 0.48a
14 21 2.72 9 6.62 10 4.74 2 1.01 0 0.00b,d
4 4 0.52 1 0.74 2 0.95 1 0.51 0 0.00
PCV13 252 32.25 75 55.15 85 40.28 57 27.78 35 16.19c
Add PCV13 122 14.77 21 15.44 48 20.38 34 16.16 19 8.57
19A 46 5.96 9 6.62 14 6.64 10 5.05 13 6.19
3 51 6.61 10 7.35 20 9.48 16 8.08 5 2.38a–d
7F 12 1.55 1 0.74 7 3.32 3 1.52 1 0.48b
6A 11 1.42 1 0.74 6 2.84 4 2.02 0 0.00b–d
1 1 0.13 0 0.00 0 0.00 1 0.51 0 0.00
5 1 0.13 0 0.00 1 0.47 0 0.00 0 0.00
non-PCV13 503 67.36 61 46.32 126 63.03 141 75.25 175 83.33b
11A 57 7.38 10 7.35 12 5.69 12 6.06 23 10.95b,d
6C 41 5.31 0 0.00 9 4.27 11 5.56 21 10.00b
31 31 4.02 4 2.94 9 4.27 5 2.53 13 6.19
23A 32 4.15 4 2.94 9 4.27 9 4.55 10 4.76
15B/C 18 2.33 1 0.74 2 0.95 6 3.03 9 4.29b,d
23B 27 3.50 5 3.68 5 2.37 9 4.55 8 3.81
35B 26 3.37 3 2.21 8 3.79 7 3.54 8 3.81
10A 25 3.24 2 1.47 7 3.32 8 4.04 8 3.81
24F 17 2.20 1 0.74 3 1.42 5 2.53 8 3.81
16F 29 3.76 7 5.15 8 3.79 7 3.54 7 3.33
15A 34 4.40 3 2.21 6 2.84 19 9.60 6 2.86c
22F 24 3.11 3 2.21 9 4.27 6 3.03 6 2.86
9L/N 12 1.55 1 0.74 3 1.42 3 1.52 5 2.38
35F 16 2.07 2 1.47 7 3.32 3 1.52 4 1.90
33F 18 2.33 6 4.41 5 2.37 6 3.03 1 0.48a,d
17F 11 1.42 0 0.00 3 1.42 6 3.03 2 0.95
34 8 1.04 0 0.00 4 1.90 2 1.01 2 0.95
8 3 0.39 0 0.00 1 0.47 0 0.00 2 0.95
21 10 1.30 2 1.47 4 1.90 4 2.02 0 0.00c
12F 8 1.04 1 0.74 4 1.90 3 1.52 0 0.00
38 5 0.65 0 0.00 5 2.37 0 0.00 0 0.00b
20 5 0.65 1 0.74 2 0.95 2 1.01 0 0.00
NT 27 3.50 0 0.00 0 0.00 4 2.02 23 10.95
Others 19 2.46 5 3.68 1 0.47 4 2.02 9 4.29
Notes: Significant changes comparing current (2013–2016) period with previous periods: a2001–2004; b2005–2008; c2009–2012; d2001–2012. Data of the historical period 
were previously published in Domenech et al.1 Values shown in bold indicate the significant data.
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Table S2 Clonal composition of major serotypes causing invasive and noninvasive diseases in COPD patients (2013–2016)
Serotype Clonal complex IPD Non-BPP AE-COPD Total
n n n n
11A Total 3 7 23 33
CC156 2 5 19 26
CC62 1 1 4 6
Others 0 1 0 1
3 Total 8 13 5 26
CC180 5 9 3 17
CC260 2 4 2 8
Others 1 0 0 1
6C Total 0 4 21 25
CC386 0 3 18 21
CC224 0 0 1 1
CC1692 0 0 1 1
CC2690 0 1 0 1
Others 0 0 1 1
19A Total 3 5 13 21
CC320 0 3 7 10
CC230 0 0 2 2
CC199 1 1 0 2
CC193 0 1 1 2
CC81 1 0 1 2
Others 1 0 2 3
31 Total 3 4 13 20
CC1684 3 4 13 20
23A Total 3 6 10 19
CC42 0 4 7 11
CC2670 2 2 2 6
Others 1 0 1 2
35B Total 2 5 8 15
CC2690 1 0 2 3
CC558 1 0 1 2
Others 0 5 5 10
8 Total 8 4 2 14
CC53 4 3 1 8
CC404 3 1 1 5
CC3500 1 0 0 1
9L/N Total 3 6 5 14
CC67 3 6 5 14
23B Total 3 2 8 13
CC338 3 0 0 3
CC2372 0 2 8 10
10A Total 2 2 8 12
CC97 1 2 7 10
Others 1 0 1 2
15BC Total 0 3 9 12
CC1262 0 2 6 8
CC199 0 1 1 2
Others 0 0 2 2
19F Total 1 0 11 12
CC202 0 0 2 2
CC179 0 0 1 1
CC87 0 0 1 1
CC90 0 0 1 1
CC8359 0 0 3 3
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COPD pneumococcal serotypes and genotypes
Table S2 (Continued)
Serotype Clonal complex IPD Non-BPP AE-COPD Total
n n n n
16F Total 0 3 7 10
CC30 0 2 6 8
Others 0 1 1 2
22F Total 2 2 6 10
CC433 1 2 5 8
Others 1 0 1 2
24F Total 0 0 8 8
CC230 0 0 8 8
12F Total 5 1 0 6
CC989 4 1 0 5
CC1766 1 0 0 1
15A Total 0 0 6 6
CC63 0 0 4 4
Others 0 0 2 2
17F Total 2 2 2 6
CC392 2 1 1 4
Others 0 1 1 2
35F Total 0 1 4 5
CC2615 0 0 3 3
CC1635 0 0 1 1
Others 0 1 0 1
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Serotype related  
(number of isolates)
2001–20041 2005–20081 2009–20121 2013–2016
136 (%) 211 (%) 198 (%) 210 (%)
156 54 9V (16) 10 7.4 4 1.9 1 0.5 0 0.0
14 (16) 7 5.1 7 3.3 2 1.0 1 0.5
11A (22) 0 0.0 0 0.0 3 1.5 19 9.0
63 35 15A (30) 3 2.2 6 2.8 17 8.6 4 1.9
19F (4) 2 1.5 1 0.5 1 0.5 0 0.0
15F (1) 1 0.7 0 0.0 0 0.0 0 0.0
62 31 11A (31) 9 6.6 10 4.7 8 4.0 4 1.9
180 28 3 (28) 7 5.1 9 4.3 9 4.5 3 1.4
30 27 16F (27) 6 4.4 8 3.8 7 3.5 6 2.9
42 27 23A (25) 4 2.9 10 4.7 5 2.5 7 3.3
19A (1) 0 0.0 1 0.5 0 0.0 0 0.0
23F (1) 0 0.0 1 0.5 0 0.0 0 0.0
386 25 6C (24), 6A (1) 0 0.0 0 0.0 7 3.5 18 8.6
81 22 23F (12) 7 5.1 5 2.3 0 0.0 0 0.0
19A (6) 3 2.2 1 0.5 1 0.5 1 0.5
19F (4) 2 1.4 2 0.9 0 0.0 0 0.0
97 22 10A (22) 2 1.5 5 2.4 8 4.0 7 3.3
260 18 3 (18) 2 1.5 7 3.3 7 3.5 2 1.0
230 17 24F (14) 0 0.0 3 1.4 3 1.5 8 3.8
19A (3) 0 0.0 1 0.5 0 0.0 2 1.0
433 15 22F (15) 1 0.7 7 3.2 2 1.0 5 2.4
320 14 19A (14) 0 0.0 1 0.5 6 3.0 7 3.3
1684 23 31 (23) 1 0.7 5 2.4 4 2.0 13 6.2
88 11 19F (11) 5 3.7 3 1.4 3 1.5 0 0.0
558 11 35B (8) 1 0.7 2 0.9 4 2.0 1 0.5
35F (3) 1 0.7 2 0.9 0 0.0 0 0.0
3548 10 31 (10) 1 0.7 5 2.4 4 2.0 0 0.0
717 11 33F (10) 3 2.2 2 0.9 5 2.5 1 0.5
191 10 7 (10) 1 0.7 5 2.4 3 1.5 1 0.5
67 10 9L/N (9), 14 (1) 2 1.5 1 0.5 2 1.0 5 2.4
432 8 21 (8) 2 1.5 4 1.9 2 1.0 0 0.0
338 18 23B (8) 2 1.5 2 0.9 6 3.0 8 3.8
989 7 12F (7) 1 0.7 4 1.9 2 1.0 0 0.0
110 7 18C (7) 4 2.9 2 0.9 0 0.0 1 0.5
1201 6 19A (6) 1 0.7 3 1.4 2 1.0 0 0.0
392 6 17F (6) 0 0.0 1 0.5 4 2.0 1 0.5
1262 6 15BC (6) 0 0.0 0 0.0 0 0.0 6 2.9
177 5 19F (5) 1 0.7 0 0.0 4 2.0 0 0.0
90 5 6B (4) 3 2.2 1 0.5 0 0.0 0 0.0
19F (1) 0 0.0 0 0.0 0 0.0 1 0.5
Note: Data of the historical period were previously published in part in Domenech et al.1
Abbreviation: AE-COPD, acute exacerbation of chronic obstructive pulmonary disease.
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